From:

Sent: 04 March 2022 09:13

To: PHARMACO - Pirmohamed, Dr M (i);

Subject: FW: RE: CHM - End of appointment letters

Attachments: CHM - Professor Shirley Price - End of appointment letter.docx;

CHM-IEAG - Professor

Jonathan S Friedland - End of appointment letter.docx; CHM-NPPEAG - Professor

Malcolm Macleod -

End of appointment letter.docx

Good Morning Sir Munir,

I am forwarding the letters again for your reference for the farewell speeches later today.

Please inform us of any amendments you wish to make on the letters before we add your signature and

send to the members (this is not urgent and can wait until next week).

will be covering todays meeting as I am unable to join.

<u>Kind</u> regards

From: Expert Committee Support (ECS) <expertcommittee@mhra.gov.uk>

Sent: 03 March 2022 09:25

To: PHARMACO - Pirmohamed, Dr M (i) <munirp@liverpool.ac.uk>

Cc: Expert Committee Support (ECS) <expertcommittee@mhra.gov.uk>;

Subject: RE: CHM - End of appointment letters

Dear Sir Munir

Please see attached the three end of appointment letters for Professors Shirley Price, Jon Friedland and

Malcolm Macleod whose appointments comes to an end on 31 March 2022.

You can also use the wording in your speech tomorrow.

Kind regards.

Commission on Human Medicines (CHM) Secretariat

Regulatory Scientific & Business Support Unit (RSBU)

Medicines and Healthcare products Regulatory Agency (MHRA)

10 South Colonnade, Canary Wharf, London E14 4PU

ECS Team:

ECS Email: expertcommittee@mhra.gov.uk

gov.uk/mhra

Stay connected

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended

recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this

email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender

immediately by using the reply function and then permanently delete what you have received. Incoming

and outgoing email messages are routinely monitored for compliance with the Department of Health's

policy on the use of electronic communications. For more information on the Department of Health's

email policy, click DHTermsAndConditions



<u>Professor</u> Shirley Price



4 March 2022

10 South Colonnade Canary Wharf London E14 4PU United Kingdom

+44 (0) 20 3080 6060

gov.uk/chm

Dear Professor Price,

As you are aware, your current term of appointment as a Commissioner to the Commission on Human Medicines (CHM) will come to an end formally on 31 March 2022.

I would like to take this opportunity to thank you for your contribution in supporting the work of the CHM. Your service began in 13 November 2007 with your appointment to the Commission's Paediatric Medicines Expert Advisory Group and as a Commissioner from 1 April 2014. In addition, you have been a member of numerous CHM Expert Working Groups, including the Hormonal Pregnancy Tests EWG 2015-2017 and those more recently as a member of the E-Cigarettes EWG 2019, the COVID-19 Vaccines Therapeutics EWG and the COVID-19 VBR EWG 2020-2022. Your participation in the meetings of the CHM and contribution of written comments when requested, have greatly supported the work of the Commission and the Agency.

The Commission depends heavily on the dedication, knowledge and experience of its experts, and we greatly appreciate and value the considerable efforts that you have put into your role over the years. We know how much preparation it takes in order to take a full part in these meetings, and you have done this with outstanding skills.

With very many thanks for your service and best wishes for the future.

Yours sincerely,

Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci

Chair of Commission on Human Medicines

- T 0203 080 6060
- E ECS.Appointments@mhra.gov.uk



Professor Jonathan S Friedland



4 March 2022

10 South Colonnade Canary Wharf London E14 4PU United Kingdom

+44 (0) 20 3080 6060

gov.uk/chm

Dear Professor Friedland,

As you are aware, your current term of appointment to the membership of the Commission on Human Medicines (CHM) and the Infection Expert Advisory Group (EAG) will come to an end formally on 31 March 2022.

I would like to take this opportunity to thank you for your contribution in supporting the work of the CHM since 1 April 2014 and as a Chair of the Infection EAG since 2015. Your participation in the meetings of the CHM and contribution of written comments when requested, have greatly supported the work of the Commission and the Agency. In addition, you have dealt with numerous CHM Expert Working Groups dealing with important and highly sensitive public health topics, including where you have been a member of the Gentamicin Ad Hoc Group in 2018 and the COVID-19 Vaccines Safety Surveillance Methodologies Expert Working Group in 2020; you have also Chaired the COVID-19 Therapeutics Expert Working Group in 2020–2022.

As you know, the Commission depends heavily on the dedication, knowledge and experience of its experts, and we greatly appreciate and value the considerable efforts that you have put into each of your roles over the years.

With very many thanks for your service and best wishes for the future.

Yours sincerely,

Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci

Chair of Commission on Human Medicines

- T 0203 080 6060
- E ECS.Appointments@mhra.gov.uk



Professor Malcolm Macleod



4 March 2022

10 South Colonnade Canary Wharf London E14 4PU United Kingdom

+44 (0) 20 3080 6060

gov.uk/chm

Dear Professor Macleod,

As you are aware, your current term of appointment to the membership of the Commission on Human Medicines (CHM) and the Commission's Neurology, Pain and Psychiatry Expert Advisory Group (EAG) will come to an end formally on 31 March 2022.

I would like to take this opportunity to thank you for your contribution in supporting the work of the CHM. Your service began in 18 April 2013 with your appointment to the Neurology, Pain and Psychiatry EAG progressing to your becoming Chair of the EAG from 2020. In addition, you have been a Chair of the CHM Anti-Epileptic Drugs Expert Working Group in 2015 and a Commissioner since 1 April 2014. Your participation in the meetings of the CHM and contribution of written comments when requested, have greatly supported the work of the Commission and the Agency.

As you know, the Commission depends heavily on the dedication, knowledge and experience of its experts, and we greatly appreciate and value the considerable efforts that you have put into each of your roles over the years.

With very many thanks for your service and best wishes for the future.

Yours sincerely,

Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci

Chair of Commission on Human Medicines

- T 0203 080 6060
- E ECS.Appointments@mhra.gov.uk